MIRM

AI Memo

Mirum

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Brelovitug Phase 3 AZURE-1 result • 2026-09-28

Base target: $94 / p=50% prob

Biggest risk

AZURE-4 could fail to replicate AZURE-1, ATEBRIOZ is launching into an ultra-rare population, and development spending remains substantial. The FDA recommended an additional Phase 3 study for volixibat in PSC at the pre-NDA meeting, creating timing risk despite Mirum's H1 2027 submission target. Mirum Q2 update

Invalidation

Break below $59 or thesis failure.

What would change my mind?

AZURE-1's positive Phase 3 result, the ATEBRIOZ approval and Q2 LIVMARLI sales of $128.7 million support multiple distinct growth avenues. Mirum raised 2026 net-product-sales guidance to $680 million–$700 million. Mirum AZURE-1 release Mirum Q2 update

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

$94

p=50%

Bull target

$125

p=30%

Bear target

$59

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ATEBRIOZ U.S.
launch
Brelovitug U.S.

BearKey bullets

ATEBRIOZ launch access and uptake remain unproven; its approved FOP population is ultra-rare.
Mirum/Incyte release
AZURE-4 efficacy or safety may not replicate AZURE-1; brelovitug remains investigational.

WatchKey bullets

Brelovitug Phase 3 AZURE-1 result

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $94 (p=50%)

Target spread vs base: +33% / -37%

Scenario probabilities

Bull Target: $125 (p=30%)Base Target: $94 (p=50%)Bear Target: $59 (p=20%)

Commentary

Company news is favorable, but the October 1 $83.92 packet anchor is about 6.4% below the prior baseline's $89.70 anchor; the two observations alone do not establish an event-day reaction or its cause. Post-readout analyst target changes are mixed in magnitude and broader estimate revisions were not verified. Numeric sentiment fields set to zero denote unavailable measurements, not neutral readings; social coverage is absent.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ATEBRIOZ U.S. launch
Brelovitug U.S. registration filing

Scenarios

Bull Target (Scenario probability)

$125 / p=30% prob

Base Target (Scenario probability)

$94 / p=50% prob

Bear Target (Scenario probability)

$59 / p=20% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-28
Brelovitug Phase 3 AZURE-1 result
On September 28, AZURE-1 met its Week 24 composite endpoint: response was 56% and 45% in the two brelovitug arms versus 0% with delayed treatment (p<0.0001 for both). This strengthens the HDV program, but a second pivotal readout remains outstanding. [#IR-2026-09-28] Mirum release
Prob 100.00% • Move 0.00% • Priced-in 80.00%
EVENT2026-12-31
Brelovitug AZURE-4 topline data
Mirum expects Q4 2026 results from AZURE-4, the second pivotal HDV study intended to support U.S. registration. Consistency with AZURE-1 efficacy and safety is the principal near-term binary risk. [#IR-2026-09-28] Mirum release
Prob 80.00% • Move 12.00% • Priced-in 40.00%
EVENT2026-12-31
LIVMARLI EXPAND Phase 3 topline data
Mirum expects Q4 2026 EXPAND data in additional rare cholestatic-pruritus settings. A positive result could support future label expansion, while a miss would narrow the existing franchise's growth path. [#IR-2026-08-05] Mirum Q2 update
Prob 75.00% • Move 7.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

ATEBRIOZ U.S. launch
2026-10-31
Following FDA approval for FOP patients aged 12 and older, Mirum expects U.S. availability in October. Access and initial uptake—not approval—are now the key uncertainties. The reported Week 24 reduction in new HO lesion volume is also supported by the September 28 SEC filing excerpt. [#8-K-2026-09-28] [#IR-2026-09-25] Mirum/Incyte release
Prob 85% • Move 4% • Priced-in 65%

Long-term Catalysts

Months to a year

Brelovitug U.S. registration filing
2027-06-30
Conditional on the remaining pivotal evidence, Mirum plans an HDV biologics-license application in H1 2027. Filing timing and the eventual FDA review remain uncertain. [#IR-2026-09-28] Mirum release
Prob 65% • Move 8% • Priced-in 30%

Risks

ATEBRIOZ launch access and uptake remain unproven; its approved FOP population is ultra-rare. Mirum/Incyte release
AZURE-4 efficacy or safety may not replicate AZURE-1; brelovitug remains investigational. Mirum AZURE-1 release
Q2 total operating expenses were $218.8 million against $176.2 million of revenue; the company held $561.3 million of unrestricted cash and investments at June 30 and issued $690 million of 2032 convertible notes. Spending and potential dilution warrant monitoring. Mirum Q2 update
The FDA recommended another Phase 3 study for volixibat in PSC; regulatory alignment on the proposed H1 2027 filing is unresolved. Mirum Q2 update

Peers

Symbol	Summary
SRRK	Rare-disease development-risk reference from the prior baseline, with limited comparability to Mirum's marketed portfolio.
INCY	Developer and worldwide licensor of zilurgisertib to Mirum, not an independent valuation peer. Mirum/Incyte release
KNSA	Rare-disease commercialization reference from the prior baseline, but its indications are not direct substitutes for Mirum's; not a clean valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

SRRK

Rare-disease development-risk reference from the prior baseline, with limited comparability to Mirum's marketed portfolio.

INCY

Developer and worldwide licensor of zilurgisertib to Mirum, not an independent valuation peer. Mirum/Incyte release

KNSA

Rare-disease commercialization reference from the prior baseline, but its indications are not direct substitutes for Mirum's; not a clean valuation multiple.